Selective RARγ ligand-loaded nanoparticles for manipulation of targeted bone growth

Patent metadata

Field	Value
Publication number	US-11833256-B2
Application number	US-201816622366-A
Country	US
Kind code	B2
Filing date	Jun 20, 2018
Priority date	Jun 20, 2017
Publication date	Dec 5, 2023
Grant date	Dec 5, 2023

Abstract

The invention relates to compositions and methods as part of a pharmacotherapeutic strategy that targets the endochondral ossification process in a pharmacologically selective and site-specific manner. A variety of orthopedic pathologies are caused by or associated with generalized or local dysregulation of endochondral ossification, for example trauma to the bone growth plate or diaphysis can cause a serious imbalance in bone growth, leading to progressive deformity that today can only be treated surgically. Dysregulated endochondral ossification is also behind heterotopic ossification, which arises in soft tissues and causes pain, decrease in mobility and other clinical problems. The invention therefore provides RARy agonist and antagonist nanoparticle compositions for treating abnormal endochondral ossification and bone growth that can deliver robust local therapeutic control over a particular long bone's growth with a long-lasting effect.

First claim

The invention claimed is:

1. A method of treating a bone growth imbalance in a discrete area of bone in a subject in need thereof, comprising administering a lyophilized nanoparticle pharmaceutical composition which comprises a poly(D,L-lactide) nanoparticle loaded with a retinoic acid receptor gamma (RARγ) modifying agent to the subject by injection,
wherein the subject does not suffer from heterotrophic ossification and wherein the RARγ modifying agent is an RARγ agonist.

2. The method of claim 1 , wherein the injection is local injection to a discrete area of bone requiring growth modification.

3. The method of claim 1 , wherein the bone growth imbalance is an imbalance of bone length, bone alignment, or both bone length and bone alignment.

Assignees

• Univ Maryland
• Childrens Hospital Of Philadelphia
• Childrens Hospital Philadelphia

Inventors

• Iwamoto Masahiro
• Chorny Michael

Classifications

• A61K31/192

  having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid  {(cannabinoids A61K31/658)} · CPC title

• A61K9/5192 Primary

  Processes · CPC title

• A61K9/19 Primary

  lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)} · CPC title

• A61K9/5153

  Polyesters, e.g. poly(lactide-co-glycolide) · CPC title

• A61K31/415

  1,2-Diazoles · CPC title